12:00 AM
Oct 25, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

FV-100: Completed Phase II enrollment

Inhibitex completed enrollment of 350 patients in a double-blind Phase II trial comparing 200 and 400 mg doses of once-daily FV-100 vs. 1,000 mg thrice-daily Valtrex valacyclovir. In July,...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >